HLB
HLB · 028300
Health Care Pharmaceuticals · KOSDAQ
Market cap US$5B (₩6.9T)
Overview
HLB is a South Korean conglomerate listed on KOSDAQ that operates across healthcare, biopharmaceuticals, and marine engineering.
Its healthcare arm supplies diagnostic test kits, blood-glucose monitoring devices, antiseptic products, and medical consumables to domestic and international pharmaceutical and diagnostics companies. Its biopharma subsidiaries are developing targeted cancer therapies, including an oral treatment for liver cancer and a licensed drug candidate for bile-duct cancer. Its marine division designs and builds specialised vessels, lifeboats, and composite piping systems for government agencies, coast guards, and shipyards.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$31.1M
- FY2024US$49.4M
- FY2025US$61M
Operating profit
- FY2023−US$90.6M
- FY2024−US$85.9M
- FY2025−US$75.5M
Net income
- FY2023−US$149.3M
- FY2024−US$78.3M
- FY2025−US$170.6M
Key ratios (FY2025)
Why it matters
HLB operates through distinct subsidiaries including Elevar Therapeutics and Immunomic Therapeutics on the biopharma side, giving it a multi-entity structure spanning Korea and overseas.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?